Blog about beauty and health!

The study showed that newly approved drugs for angina can also serve as a powerful new tool to combat a rare hereditary symptom, which endangers young people and teenagers unpredictable death from cardiac arrest.
The analysis results were presented at the 57 - Annual Scientific Congress of the American College of Cardiology in Chicago.
Cardiac arrhythmia - a violation of frequency, rhythm and consistency cuts of heart divisions. The disease kills around 330 thousand inhabitants of America annually.
The most deaths observed among older people who have experienced a heart attack. However, about a thousand deaths a consequence of so-called QT interval elongated syndrome, which manifests itself in young people in their teens.
During the current analysis, scientists have found that a new drug ranolazine, also known as Ranexa, shortens QT intervals at 5%, which is sufficient to prevent the development of the heart arrhythmia.
Previous analyses have indicated that patients suffering from angina, acute pain in the throat, also tend to develop arrhythmia. Thus, the new drug is struggling with a complex disease.